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Pathway-based analysis of primary biliary cirrhosis genome-wide
association studies
SP Kar1,2, MF Seldin3,4, W Chen1, E Lu1, GM Hirschfield5,6, P Invernizzi3,7, J Heathcote8, D Cusi9,10 the Italian PBC Genetics Study Group11,
ME Gershwin3, KA Siminovitch12,13 and CI Amos1,14
Genome-wide association studies (GWAS) have successfully identiﬁed several loci associated with primary biliary cirrhosis (PBC) risk.
Pathway analysis complements conventional GWAS analysis. We applied the recently developed linear combination test for
pathways to datasets drawn from independent PBC GWAS in Italian and Canadian subjects. Of the Kyoto Encyclopedia of Genes
and Genomes and BioCarta pathways tested, 25 pathways in the Italian dataset (449 cases, 940 controls) and 26 pathways in the
Canadian dataset (530 cases, 398 controls) were associated with PBC susceptibility (Po0.05). After correcting for multiple
comparisons, only the eight most signiﬁcant pathways in the Italian dataset had FDR o0.25 with tumor necrosis factor/stress-
related signaling emerging as the top pathway (P¼ 7.38 10 4, FDR¼ 0.18). Two pathways, phosphatidylinositol signaling and
hedgehog signaling, were replicated in both datasets (Po0.05), and subjected to two additional complementary pathway tests.
Both pathway signals remained signiﬁcant in the Italian dataset on modiﬁed gene set enrichment analysis (Po0.05). In both GWAS,
variants nominally associated with PBC were signiﬁcantly overrepresented in the phosphatidylinositol pathway (Fisher exact
Po0.05). These results point to established and novel pathway-level associations with inherited predisposition to PBC that, on
further independent replication and functional validation, may provide fresh insights into PBC etiology.
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INTRODUCTION
Primary biliary cirrhosis (PBC) is the most common autoimmune
liver disease and primarily affects women, with a prevalence of 1
in 1000 over the age of 40 years.1 The serological hallmark of
PBC is the formation of anti-mitochondrial antibodies against
the pyruvate dehydrogenase complex subunit E2 (PDC-E2).2
The antibodies speciﬁcally recognize immunoreactive PDC-E2
within apoptotic blebs of biliary epithelial cells.3 Untreated
disease involves progressive, non-suppurative granulomatous
inﬂammation and autoreactive T lymphocyte-mediated
destruction of the small-to-medium intrahepatic bile ducts
leading to chronic cholestasis, portal inﬂammation, cirrhosis and
end-stage liver disease.4 The accepted concept of PBC etiology is
that it arises on a background of strong genetic susceptibility that
is reactive to a variety of potential environmental triggers. The
disease has a monozygotic concordance of 63%,5 a sibling relative
risk of 10.5,6 and 1–6% of all patients with PBC have at least one
ﬁrst-degree relative affected.7 Other autoimmune disorders also
tend to be more common in the families of PBC cases.8 To date,
there have been three genome-wide association studies (GWAS)
for PBC that have reproducibly identiﬁed several risk loci that
implicate key gene loci involved in adaptive immunity and
inﬂammatory response.9–12
The genetic associations with PBC risk identiﬁed by the
genome-wide approach are just those single nucleotide poly-
morphisms (SNPs) that met the most stringent criterion for
statistical signiﬁcance applied to account for the exceedingly large
number of statistical comparisons made in a GWAS. Many more
variants are typically associated with disease only at the nominal
signiﬁcance level in a GWAS and are therefore not investigated
further.13 However, if the excess familial risk for PBC is to be
explained, some of these discarded variants must be false
negatives and constitute genuine PBC susceptibility loci.
Moreover, due to population genetic heterogeneity, different
SNPs in or near the same gene or in a functionally related gene
may be associated with the disease among individual cases in a
GWAS sample. This makes it less likely that a replicable association
with the disease would be found when testing SNPs one at a time
as is usually done in a GWAS.14 Single nucleotide polymorphisms
and the genes that they belong to are not random entities. The
products of speciﬁc sets of genes interact as members of discrete
molecular and cellular pathways with deﬁned biological
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function.15 Collectively, these observations have motivated the
development of methods for the secondary or complementary
statistical analysis of GWAS data that use biological pathways
represented by gene sets, instead of SNPs, as the units of
analysis.16 Pathway-based tests provide a dynamic biologically
plausible template to efﬁciently integrate statistical information
from the multitude of SNPs with weaker effects that are otherwise
missed by conventional single-SNP GWAS analysis.17
In GWAS pathway analysis, one can map SNPs to genes and test
for overrepresentation of statistically signiﬁcant association signals
among genes within a known biological pathway compared with
the number of such signals among genes outside the pathway.
This is termed the ‘competitive’ approach.16 Alternatively, one can
jointly test all genes within the pathway for an association with
the disease. As the latter only considers disease association signals
within a pathway and does not compare them to signals outside
the pathway, it is termed the ‘self-contained’ approach. So far,
these methods have been successfully employed to analyze GWAS
of a diverse group of diseases.18,19 Here, we report the results of
pathway analysis of two datasets from previously completed
GWAS in independent Italian and Canadian PBC cohorts. We
applied a recently developed ‘self-contained’ GWAS pathway
analysis method, the linear combination test (LCT) of Luo et al.,20
to identify pathways associated with genetic predisposition to PBC
and provide greater insight into the etiology of this complex
autoimmune disease. In accordance with recommendations for
validating GWAS pathway analysis ﬁndings by complementary
methods,14,21 the statistical signiﬁcance of top pathways that were
replicated in both datasets was further conﬁrmed by using two
‘competitive’ pathway-oriented strategies.
RESULTS
Linear combination test for pathway analysis
First, we individually analyzed the Italian and Canadian datasets
using the LCT.20 This algorithm uses raw genotype data to ﬁrst
compute genome-wide single-SNP association statistics (see
Material and methods for details). After assigning all SNPs
between the start site and the 30 untranslated region to a gene,
single-SNP P-values were combined for each gene using the gene-
level LCT statistic derived by Luo, et al.20 Genes were classiﬁed into
pathways using the well-accepted Kyoto Encyclopedia of Genes
and Genomes (KEGG) and BioCarta resources. Finally, gene-level
statistics for all genes within a pathway were combined using the
pathway-level LCT (see Material and methods). For these tests, we
set Po0.05 and false discovery rate (FDR) o0.25 as a stringent
criteria for signiﬁcance (Material and methods).
In the Italian dataset, 207 695 SNPs out of 468 982 SNPs were
located within genes and mapped to 14 527 genes. Of these, 4172
genes were assigned to pathways for LCT analysis. In the Canadian
dataset, 143 059 SNPs out of 334 444 SNPs were located within
genes and mapped to 14 792 genes. Of these, 4226 genes were
assigned to pathways for LCT analysis. Pathways with 410 genes
accounted for 175 BioCarta and 172 KEGG pathways in the Italian
study and 176 BioCarta and 172 KEGG pathways in the Canadian
study. At the gene-level, the LCT identiﬁed 253 genes in the Italian
sample and 236 genes in the Canadian sample with P-value
o0.05. These genes are listed in Supplementary Table S1. As
shown in Supplementary Table S2, there was limited overlap
between signiﬁcant genes in the two datasets.
Pathways suggested from the linear combination test analyses
At the pathway-level, the LCT identiﬁed 25 pathways (13 BioCarta,
12 KEGG) in the Italian dataset at the Po0.05 level (Table 1). Of
these, eight pathways achieved the threshold for statistical
signiﬁcance we set for this study (Po0.05 and FDRo0.25).
Notably, these eight included three pathways that are likely to
be important in the pathogenesis of inﬂammatory and auto-
immune processes: tumor necrosis factor (TNF)/stress-related
signaling pathway (P¼ 7.38 10 4, FDR¼ 0.18), antigen proces-
sing and presentation (P¼ 1.08 10 3, FDR¼ 0.18), and chaper-
ones modulate interferon signaling pathway (P¼ 2.33 10 3,
FDR¼ 0.192).
There were 26 pathways (8 BioCarta, 18 KEGG) in the Canadian
dataset at the Po0.05 level using LCT analysis (Table 2). None of
these pathways met the more stringent criterion for statistical
signiﬁcance (Po0.05 along with FDRo0.25). However, three of the
pathways had an FDR of o0.5: regulation and function of
carbohydrate-responsive element-binding protein (ChREBP) in
liver pathway (P¼ 5.68 10 4, FDR¼ 0.285), bone remodeling
pathway (P¼ 2.33 10 3, FDR¼ 0.493) and apoptosis (P¼ 3.96
 10 3, FDR¼ 0.493). For both datasets, there was no signiﬁcant
correlation between the number of genes in a pathway and
pathway rank. Complete LCT pathway analysis results for the
Italian dataset are presented in Supplementary Table S3 and for
the Canadian dataset in Supplementary Table S4. We also present
the pathway results from both datasets combined using Fisher’s
method for meta-analysis in Supplementary Table S5.
Two pathways reached the Po0.05 level in both datasets using
the LCT. They were the phosphatidylinositol signaling system
(Italian: P¼ 0.016, FDR¼ 0.436; Canadian: P¼ 0.034, FDR¼ 0.693;
meta-analysis P¼ 4.48 10 3) and the hedgehog signaling
pathway (Italian: P¼ 0.044, FDR¼ 0.636; Canadian: P¼ 0.041,
FDR¼ 0.693; meta-analysis P¼ 0.013).
Complementary analyses supports speciﬁc pathways
The phosphatidylinositol signaling system and the hedgehog
signaling pathways were followed up in each dataset by two
complementary pathway analysis methods (Table 3). First, we
applied i-GSEA4GWAS, a modiﬁcation of the gene set enrichment
analysis (GSEA) approach that uses SNP label permutation (see
Material and methods).22 Using the i-GSEA4GWAS algorithm, the
association between the phosphatidylinositol signaling system
pathway and PBC was found to be statistically signiﬁcant in the
Italian dataset (P¼ 0.003), but not in the Canadian sample.
Similarly, the hedgehog signaling pathway yielded signiﬁcant
results on i-GSEA4GWAS in the Italian dataset only (P¼ 0.005).
Second, we used Fisher’s exact test as a measure of signiﬁcance
for the proportion of the total genes in each pathway that
contained at least one SNP with P-valueo0.05 (see Material and
methods for details). Applying Fisher’s exact test, pathway
enrichment ratios for the phosphatidylinositol signaling system
were signiﬁcant in both cohorts (Italian: P¼ 1.42 10 5; Cana-
dian: P¼ 3.45 10 4) with 32 out of 77 genes and 26 out of 77
genes from this pathway containing at least one SNP with Po0.05
in the Italian and Canadian GWAS, respectively. Although hedge-
hog signaling also demonstrated enrichment in both datasets,
ratios for this pathway were not statistically signiﬁcant (Table 3).
To further dissect the LCT pathway analysis association signal
for these two pathways in each dataset, we examined the most
signiﬁcant genes underlying the signals (Figure 1). The genes most
strongly driving the association for each replicated pathway
differed between the two datasets pointing to the genetic
heterogeneity and complexity of the disease under study and
power limitations in the dataset sample numbers, especially for
ascertaining genes with smaller effect size.
DISCUSSION
In this study, we used a newly developed pathway-based method,
the LCT, to analyze two datasets obtained from previously
completed GWAS of Italian and Canadian PBC cohorts. At the
conservative cutoff for statistical signiﬁcance (Po0.05 and
FDRo0.25) that we adopted, the LCT identiﬁed eight pathways
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associated with the risk of development of PBC in the Italian
dataset. We leveraged the availability of data from the two
independent, geographically separated PBC case populations to
evaluate our ﬁndings more broadly. In the interpretation of our
results, we focus on those pathways that showed nominal
evidence of association in both the Italian and in the Canadian
Table 2. Pathways identified in the Canadian dataset using linear combination test analysisa
Rank Pathway name Source Pathway size (genes) P-value (LCT) FDR
1 Regulation and function of ChREBP in liver pathway BioCarta 44 0.0006 0.285
2 Bone remodeling pathway BioCarta 14 0.0023 0.493
3 Apoptosis KEGG 90 0.0040 0.493
4 Renal cell carcinoma KEGG 69 0.0101 0.648
5 Phenylalanine metabolism KEGG 21 0.0102 0.648
6 Keratan sulfate biosynthesis KEGG 16 0.0114 0.648
7 DNA replication KEGG 36 0.0128 0.648
8 Tyrosine metabolism KEGG 46 0.0129 0.648
9 Stress induction of HSP regulation pathway BioCarta 15 0.0152 0.693
10 The IGF-1 receptor and longevity pathway BioCarta 15 0.0183 0.693
11 Amyotrophic lateral sclerosis (ALS) KEGG 19 0.0204 0.693
12 Regulation of BAD phosphorylation pathway BioCarta 26 0.0247 0.693
13 Basal cell carcinoma KEGG 55 0.0285 0.693
14 Role of mitochondria in apoptotic signaling pathway BioCarta 21 0.0329 0.693
15 Colorectal cancer KEGG 85 0.0332 0.693
16 Phosphatidylinositol signaling system KEGG 77 0.0335 0.693
17 Cytokine–cytokine receptor interaction KEGG 263 0.0365 0.693
18 Wnt signaling pathway KEGG 150 0.0375 0.693
19 Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway BioCarta 20 0.0385 0.693
20 Hedgehog signaling pathway KEGG 57 0.0407 0.693
21 Adherens junction KEGG 78 0.0434 0.693
22 IL-10 anti-inflammatory signaling pathway BioCarta 17 0.0457 0.693
23 Carbon fixation KEGG 24 0.0460 0.693
24 Bladder cancer KEGG 42 0.0460 0.693
25 Ubiquitin-mediated proteolysis KEGG 135 0.0476 0.693
26 Biosynthesis of phenylpropanoids KEGG 33 0.0478 0.693
Abbreviations: FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; LCT, linear combination test. aAll pathways with Po0.05 are
shown.
Table 1. Pathways identified in the Italian dataset using linear combination test analysisa
Rank Pathway name Source Pathway size
(genes)
P-value
(LCT)
FDR
1 TNF/stress-related signaling pathway BioCarta 25 0.0007 0.180
2 Role of MAL in Rho-mediated activation of SRF pathway BioCarta 19 0.0009 0.180
3 Antigen processing and presentation KEGG 88 0.0011 0.180
4 Hypoxia and p53 in the cardiovascular system pathway BioCarta 23 0.0019 0.192
5 Glycerophospholipid metabolism KEGG 66 0.0022 0.192
6 Chaperones modulate interferon signaling pathway BioCarta 19 0.0023 0.192
7 Small cell lung cancer KEGG 87 0.0035 0.218
8 Acetylation and deacetylation of RelA in the nucleus pathway BioCarta 16 0.0047 0.245
9 Signal transduction through IL1R pathway BioCarta 33 0.0059 0.269
10 CBL-mediated ligand-induced downregulation of EGF receptors pathway BioCarta 13 0.0066 0.276
11 Rho cell motility signaling pathway BioCarta 32 0.0092 0.333
12 Role of PI3K subunit p85 in the regulation of actin organization and cell migration
pathway
BioCarta 16 0.0120 0.377
13 Non-small cell lung cancer KEGG 54 0.0154 0.436
14 Phosphatidylinositol signaling system KEGG 77 0.0156 0.436
15 VEGF signaling pathway KEGG 74 0.0232 0.582
16 Calcium signaling pathway KEGG 179 0.0282 0.582
17 CD40L signaling pathway BioCarta 15 0.0300 0.582
18 Endometrial cancer KEGG 52 0.0311 0.582
19 Cyclins and cell Cycle regulation pathway BioCarta 23 0.0313 0.582
20 MAPK signaling pathway KEGG 267 0.0335 0.582
21 Complement and coagulation cascades KEGG 69 0.0383 0.636
22 Hedgehog signaling pathway KEGG 57 0.0438 0.636
23 Graft-versus-host disease KEGG 42 0.0460 0.636
24 Ras-independent pathway in NK cell-mediated cytotoxicity pathway BioCarta 20 0.0469 0.636
25 Classical complement pathway BioCarta 14 0.0484 0.639
Abbreviations: FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; LCT, linear combination test. aAll pathways with Po0.05 are
shown.
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dataset, and emphasize that GWAS pathway analysis is primarily a
tool to generate hypothesis for further testing. Two KEGG
pathways, phosphatidylinositol signaling and hedgehog signaling
systems, attained the Po0.05 level of signiﬁcance on LCT pathway
analysis in both datasets but did not meet the FDRo0.25 criterion
in either dataset. Both pathways were signiﬁcant in the larger
(Italian) dataset by a modiﬁed GSEA, further suggesting their
involvement in PBC genetic susceptibility. Simple pathway
enrichment ratios for phosphatidylinositol signaling also remained
statistically signiﬁcant in both datasets using Fisher’s exact test.
Current experimental evidence offers a variety of putative
mechanisms that may underpin the possible role of phosphati-
dylinositol and hedgehog signaling activity in PBC etiology. Each
of these mechanisms serves as a potential avenue that requires
follow-up functional investigation.
The phosphatidylinositol signaling system pathway is an
integral component of the adaptive immune response and
is essential for the maintenance of self-tolerance.23
Phosphatidylinositol signaling is known to be a key controller of
T helper 17 cell differentiation.24,25 T helper 17 cells, a subset
of helper T cells that produce interleukin 17, are major drivers of
both inﬂammation and autoimmunity.26 T helper 17
differentiation may be modulated by dendritic cell interleukin 12
(IL-12) through its effect on interferon-g.27 It has been
demonstrated that dendritic cell IL-12 production is in turn
positively regulated by the p110 b catalytic subunit of
phosphoinositide 3-kinase (PI3K).28 Interestingly, the PIK3CB
gene coding for the PI3K p110b isoform, emerged as the most
signiﬁcant gene of the phosphatidylinositol pathway in the Italian
data (P¼ 9.54 10 4, Figure 1a). The importance of IL-12 to PBC
pathogenesis is highlighted by the identiﬁcation of a strong and
reproducible association between the IL12A and IL12RB2 loci and
disease risk in every PBC GWAS conducted thus far.9–12 Further,
aberrant signal transduction via the phosphatidylinositol system in
PBC is consistent with the role of this pathway in disorders that
share genetic susceptibility factors with PBC, especially
rheumatoid arthritis and systemic lupus erythematosus.29,30
Several pathways biologically related to phosphatidylinositol
signaling were also uncovered using the LCT analysis at the
Po0.05 level in our data. A possible non-biological explanation for
this observation is that genes common to these different
pathways underlie the statistical association. However, pathway
overlap cannot account entirely for this observation and there are
well-established functional connections between the pathways
discovered and events upstream and downstream of the
phosphatidylinositol signaling system. One particularly note-
worthy relationship involves TNF/stress-related signaling, the top
pathway in the Italian dataset. This ﬁnding corroborates the
independent discovery of seven distinct loci harboring genes
related to TNF signaling and downstream Nuclear Factor-KappaB
(NF-kB) signaling at the genome-wide signiﬁcance level in the
most recent GWAS of PBC.12 Interactions between speciﬁc
members of the TNF pathway lead to the induction of apoptosis
as well as the activation of NF-kB signaling, which is anti-apoptotic
and pro-inﬂammatory.31 Disturbances in this balance between cell
death and survival are now recognized as being critical to PBC
progression.32 Possible involvement of the phosphatidylinositol
pathway in PBC thus appears to ﬁt well with the TNF hypothesis as
this signaling system has been shown to mediate the effects of
TNF-a on NF-kB activation.33,34
The hedgehog signaling pathway consists of a family of
molecules that control cell-type speciﬁcation during normal
development and are intimately involved in tissue and organ
morphogenesis.35 Biliary epithelial cells are the ﬁrst targets of
autoimmune injury in PBC. Increased expression in biliary
epithelial cells of hedgehog pathway genes and genes targeted
by this pathway has previously been reported in a study of PBC
patients.36 Animal models of chronic cholestatic biliary injury also
demonstrate activation of hedgehog signaling37 and hedgehog
signaling has been linked to the promotion of cholangiocyte
chemokine production that may mediate recruitment of
inﬂammatory cells in PBC.38 Multiple lines of evidence suggest
that the hepatic ﬁbrosis seen in the natural history of PBC can be
partly attributed to epithelial–mesenchymal transition, or to the
progressive replacement of biliary epithelial cells by cells of
ﬁbroblastic lineage.39 Hedgehog signaling is among the best-
known effectors of epithelial–mesenchymal transition.40 Another
inducer of epithelial–mesenchymal transition, the Wnt signaling
pathway (KEGG), ranked 17th among the pathways in the
Canadian sample (P¼ 0.037, FDR¼ 0.693).41 Crucially, our
analysis of the Italian cohort revealed that the ZIC2 gene,
which is pivotal to the cross-talk between hedgehog and Wnt,
was the most signiﬁcant gene not only in the hedgehog
pathway, but also for the dataset overall (P¼ 7.20 10 5,
Supplementary Table S1).42 The association between Wnt
signaling and PBC remains to be elucidated, though the
upregulation of genes in this pathway has been reported in an
early microarray study of the disorder.43
It is worth noting that the two additional analyses that we used
to evaluate the pathways replicated at the Po0.05 threshold,
complement the LCT. Taken together, they test the association
between a set of genes and disease predisposition under some of
the different underlying genetic architectures that may drive such
an association. Although the LCT combines evidence of associa-
tion from all SNPs that map to a gene, the modiﬁed GSEA only
accounts for the top SNP signal in each gene and Fisher’s exact
test for overrepresentation considers all SNPs in a gene that were
nominally signiﬁcant in the original GWAS.
Table 3. Complementary tests for pathways identified at the Po0.05 level in both datasets using LCT
Pathway namea LCT GSEAb Fisher’s exact test
Italian Canadian Italian Canadian Italian Canadian
P-value P-value P-value P-value P-value P-value
(FDR) (FDR) (Ratioc) (Ratioc)
Phosphatidylinositol signaling system 0.0156 0.0335 0.003 NS 1.4E-04 0.0003
(0.436) (0.693) (0.416) (0.338)
Hedgehog signaling pathway 0.0438 0.0407 0.005 NS 0.103 1.000
(0.636) (0.693) (0.281) (0.158)
Abbreviations: FDR, false discovery rate; GSEA, gene set enrichment analysis; LCT, linear combination test; NS, not significant. aThese pathways were defined in
the Kyoto Encyclopedia of Genes and Genomes (KEGG). bThis analysis was performed using the i-GSEA4GWAS modification of GSEA. cRatio of number of
genes containing at least one SNP with Po0.05 to the total number of genes in the pathway.
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Our study has several limitations and the results must be
interpreted with some caution. The ﬁrst, and a frequently cited
criticism of GWAS pathway analyses in general, was the reliance
on canonical pathways that representedo30% of the total genes
mapped in each dataset. However, we sought to reduce the
inﬂuence of selecting canonical pathways by sourcing our
pathways from two standard, manually curated databases
containing well-deﬁned pathways. Second, the annotation of
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Figure 1. Genes identified in the phosphatidylinositol and hedgehog signaling pathways. Genes reaching statistical significance for the
phosphatidylinositol signaling system (panel a) and the hedgehog pathway (panel b) are shown by color highlights (red, Italian dataset; blue,
Canadian dataset).
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protein-coding regions in the human genome is incomplete and
moreover, there is substantial non-coding SNP information in
intergenic regions that is now known to have both trans-effects as
well as long distance cis-effects on the expression of genes in
signaling pathways.44 Using SNPs within or close to a gene to
represent the gene overlooks such distant functional and
regulatory relationships. Third, pathways in the Canadian dataset
failed to breach the FDR level for statistical signiﬁcance that we set
and the FDRs of the pathways replicated in both datasets was
relatively high. Possible explanations include an inadequate
sample size, the behavior of the LCT statistic or the genuine
absence of a stronger pathway-level association signal for the
pathways tested. The sample size for the study was limited, but
PBC is an uncommon disease and assembling large cohorts is
difﬁcult. Lastly, the current study was limited to common SNPs
(45%) in the populations studied and many uncommon SNPs as
well as structural variants may underlie a considerable portion of
the susceptibility to this disease.
In conclusion, the linear combination method may be useful as
a secondary step to single-marker analysis for mining a combina-
tion of known and novel biologically plausible disease-related
pathways from GWAS data. Pathways such as TNF signaling,
antigen processing and presentation, and apoptosis, each of
which is an established contributor to genetic predisposition to
PBC, were among the top pathways identiﬁed.12 Two pathways,
phosphatidylinositol signaling system and hedgehog signaling,
were replicated at the nominal level of signiﬁcance in the available
datasets and these ﬁndings were backed by a complementary
pathway analysis approach in at least one of the datasets. Genetic
variation in these two pathways has not been frequently
associated with PBC in prior work. The ﬁndings need to be
validated in other independent PBC GWAS cohorts. If explored in
greater depth and conﬁrmed by future experimental studies,
these results have the potential to yield new targets that may be
of value for preventive intervention and therapeutic development
against PBC.
MATERIALS AND METHODS
Study populations
This study included both an Italian and a Canadian cohort. All PBC cases in
both GWAS met the American Association for the Study of Liver Diseases
diagnostic criteria for PBC.
The Italian dataset consisted of 449 PBC cases and 940 controls of
homogenous Italian descent with genotypes for 468 982 SNPs from the
GWAS described in detail by Liu et al.11 All retained subjects had
homogeneous Italian descent genetically inferred by principal components
analysis that applied speciﬁc criteria to eliminate outliers and individuals of
Sardinian origin from the dataset. The cases had a mean age of 55.2 years,
90.3% were female, 85.4% were anti-mitochondrial antibodies- positive
and 31.7% had liver cirrhosis. Stringent quality control standards were
implemented as previously described and all SNPs retained had sample
call rates 495%, minor allele frequency 40.05 and were in Hardy–
Weinberg disequilibrium test P410 5. Pairs of subjects with cryptic
relatedness as deﬁned by an identity-by-state score 40.1 were removed.
The Canadian sample was from the GWAS described in Hirschﬁeld et al.9
and consisted of 530 PBC cases, 398 controls and 334 444 SNPs. The cases
had a mean age of 60.7 years, 93% were female, 95.5% were anti-
mitochondrial antibodies- positive and 5.2% had received a liver
transplant. Study genotyping was done at the University of Toronto
using the Illumina HumanHap370 BeadChip. Single nucleotide
polymorphisms with minor allele frequency o0.01 were excluded and
cryptically related individuals, who had an identity-by-state score 40.25,
were removed. Other data ﬁltering standards were identical to the
Italian GWAS.
Ethics statement
All participants in both primary studies provided written informed consent
and were enrolled on protocols approved by a local Institutional Review
Board or ethics committee at each center.
Linear combination test for pathway analysis
The two datasets were analyzed individually using the LCT described by
Luo et al.20 The test was made publicly available as part of a free software
package that was used for the present pathway analysis (https://
sph.uth.tmc.edu/hgc/faculty/xiong/software-A.html). The LCT provided
adequate type I error rates in simulation studies that we conducted. The
algorithm used raw genotype data to ﬁrst compute genome-wide
single-SNP association statistics. All SNPs between the start site and the
30-untranslated region were then assigned to the gene using NCBI dbSNP
Build 129 and human Genome Build 36.3. As SNPs within genes are
correlated due to linkage disequilibrium, traditional methods for
combining independent P-values cannot be used to bring together
single-SNP P-values for all SNPs in the gene. Therefore, to test the
association of each gene with the disease, we combined P-values for all
SNPs within the gene using the gene-level LCT statistic derived by
Luo, et al.:20
TL¼ e0Zﬃﬃﬃﬃﬃﬃﬃe0Rgep
where e¼ [1,1,y,1]T. Z¼ [Z1,y, Zk]T for a gene with k SNPs (given that
Zi¼F 1(1 Pi) where, Pi is the P-value of a statistic with a normal or
asymptotic normal distribution), Rg is the correlation matrix of Z and TL
follows a standard normal distribution under the null hypothesis.
Genes were mapped to pathways from the BioCarta database (http://
www.biocarta.com/genes/index.asp) and from the Kyoto Encyclopedia of
Genes and Genomes (KEGG; http://www.genome.jp/kegg/pathway.html).
The default pathway list included with the LCT software contained 299
BioCarta and 202 KEGG pathways. However, we decided to conﬁne the
ﬁnal analysis to pathways containing410 genes to avoid testing pathways
that were too small. At this stage, P-values for all genes within a pathway
were combined using the pathway-level LCT statistic to test association of
each pathway with the disease:
TP¼ e
0TL
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
e0RPe
p
where TL¼ [TL1,y,TLm]T for a pathway with m genes. RP is the matrix of
correlations between the test statistics for all genes in the pathway and TP
is asymptotically distributed as the standard normal distribution under the
null hypothesis.
Results of the LCT analysis were adjusted for multiple comparisons using
FDR control by the Benjamini–Hochberg procedure.45 Statistical
signiﬁcance was set at Po0.05 and q-value or FDR o0.25, a frequently
adopted criterion in GWAS pathway studies.16 A meta-analysis of LCT
pathway resulting from both datasets was also conducted using Fisher’s
combined probability test.
Additional analyses for replicated pathways
To further validate pathways that were replicated at the nominal
signiﬁcance level (LCT pathway Po0.05) in both datasets, we conducted
additional GWAS pathway analyses on each dataset focused only on the
replicated pathways using two complementary strategies.
First, we used the i-GSEA4GWAS adaptation of the classical GSEA
genome-wide pathway association method.22 Classical GSEA, as in Wang
et al.,46 uses the single-SNP association test statistic for the most signiﬁcant
SNP in each gene to represent the gene. All genes are ranked in
descending order of their test statistic value. A weighted Kolmogorov–
Smirnov-like running sum statistic is calculated to determine, within a
particular pathway, overrepresentation of highly ranked genes from the
ranked list of all genes. The Kolmogorov–Smirnov-like statistic is normal-
ized to account for differences in the number of genes across pathways.
After this point, i-GSEA4GWAS differs from classical GSEA in that it
multiplies the normalized statistic by a correction factor. This factor
depends on the proportion of signiﬁcant genes in a pathway and
attenuates the possibility of pathways being unduly inﬂuenced by a few
genes that are very highly ranked. Finally, statistical signiﬁcance for
pathways is calculated after phenotype label permutation in classical
GSEA and SNP label permutation in i-GSEA4GWAS. Single nucleotide
polymorphisms are permuted across pathways and the method provides a
computationally efﬁcient approach to follow-up results from a more
comprehensive primary pathway analysis. For i-GSEA4GWAS, we (a) used
single-SNP w2 GWAS analysis results from PLINK (version 1.05) for each
dataset,47 (b) tested only those pathways that replicated on LCT in both
datasets, (c) used pathway deﬁnitions identical to LCT, (d) used the same
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rules for mapping SNPs to genes as in LCT and (e) performed 1000 SNP
label permutations.
The second complementary pathway analysis strategy for validation
involved determining the statistical signiﬁcance of pathway enrichment
ratios using Fisher’s exact test. For each dataset, all genes containing at
least one SNP with P-value o0.05 in single-SNP w2 GWAS analysis were
listed. Enrichment ratio for a pathway was calculated as the number of
genes in this list that map to the pathway divided by the number of genes
in the pathway. As before, only pathways that replicated on LCT in both
datasets were tested using pathway deﬁnitions identical to LCT. Fisher’s
exact test was used to determine the probability that the association
between genes in the list and genes in the pathway was explained by
chance alone. Data were analyzed through the use of IPA (Ingenuity
Systems, www.ingenuity.com).
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